PET/MRI in the Diagnosis of Hormone-Producing Pituitary Microadenoma: A Prospective Pilot Study.

Wang, Hao; Hou, Bo; Lu, Lin; Feng, Ming; Zang, Jie; Yao, Shaobo; Feng, Feng; Wang, Renzhi et al. · J Nucl Med · 2018

prospective_cohort · Level II

Where this comes from

Abstract

This study was designed to evaluate the ability of PET/MRI, using <sup>18</sup>F-FDG and <sup>68</sup>Ga-DOTATATE as tracers, to detect hormone-producing pituitary microadenoma when diagnosis is difficult using MRI alone. <b>Methods:</b> We recruited 37 patients with elevated hormone levels, including 19 with undiagnosable primary pituitary adenoma and 18 with suspected recurrent pituitary adenoma. <sup>18</sup>F-FDG PET/MRI and <sup>68</sup>Ga-DOTATATE PET/MRI were performed within 1 wk of each other in all patients. Within 2 wk afterward, 27 of the 37 patients underwent transsphenoidal adenomectomy, 3 underwent sella region radiotherapy, 1 underwent somatostatin therapy, and 6 had only clinical follow-up. The image characteristics and uptake levels were correlated with the surgical findings and pathologic results. Receiver-operating-characteristic curves were analyzed to determine the optimal cutoff to differentiate adenoma from normal pituitary tissue. The area under the receiver-operating-characteristic curve was calculated to compare diagnostic performance. <b>Results:</b> The PET/MR images were of diagnostic quality and without obvious image artifacts. The high contrast of the PET images provided complementary information to the fine anatomic display of the MR images. Increased <sup>18</sup>F-FDG uptake was clearly observed in all patients. MRI enhanced using a 0.05 mmol/kg dose of gadopentetate dimeglumine showed suggestive findings in only 47% of the patients with primary adenoma and 39% of those with recurrent adenoma; when a 0.1 mmol/kg dose was used, the respective percentages were 37% and 50%. The <sup>18</sup>F-FDG SUV<sub>max</sub> of the 16 primary adenomas that underwent transsphenoidal adenomectomy (6.8 ± 3.7) was significantly higher than that of normal pituitary tissue (3.2 ± 1.1, <i>P <</i> 0.01). The adenomas showed moderate <sup>68</sup>Ga-DOTATATE uptake (SUV<sub>max</sub>, 3.8 ± 2.6), but the <sup>68</sup>Ga-DOTATATE uptake was generally lower than that of normal pituitary tissue (SUV<sub>max</sub>, 6.2 ± 3.2, <i>P <</i> 0.05). In the 11 suspected recurrent pituitary adenomas that underwent transsphenoidal adenomectomy, the <sup>18</sup>F-FDG SUV<sub>max</sub> was 6.1 ± 3.5, significantly higher than that of normal pituitary tissue (2.5 ± 1.1, <i>P</i> < 0.01), and the <sup>68</sup>Ga-DOTATATE SUV<sub>max</sub> was 3.0 ± 1.1, significantly lower than that of normal pituitary tissue (5.5 ± 1.7, <i>P</i> < 0.01). The <sup>18</sup>F-FDG/<sup>68</sup>Ga-DOTATATE SUV<sub>max</sub> ratio of the adenomas (2.3 ± 1.5) was significantly higher than that of normal pituitary tissue (0.6 ± 0.3, <i>P</i> < 0.05). When the <sup>18</sup>F-FDG SUV<sub>max</sub> alone and the <sup>18</sup>F-FDG/<sup>68</sup>Ga-DOTATATE SUV<sub>max</sub> ratio were used as criteria to discriminate between adenoma and pituitary tissue, the best analysis came from the ratio, and that from <sup>18</sup>F-FDG SUV<sub>max</sub> alone was slightly less, with optimal diagnostic cutoffs of 1.04 and 3.88, respectively. <b>Conclusion:</b> PET/MRI provides an ideal tool for the detection of hormone-producing pituitary microadenoma. Dual-tracer <sup>18</sup>F-FDG and <sup>68</sup>Ga-DOTATATE PET/MRI was useful for distinguishing pituitary microadenoma from normal pituitary tissue.

Medical subject headings